Overview

Study EvAluating Genotypes While Using Lucentis 2

Status:
Completed

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms

Phase:

Phase 4

Details

Lead Sponsor:

University of California, San Diego

Collaborator:

Genentech, Inc.

Treatments:

Ranibizumab